Farmas USA

ZSAN al hoyo un 50%
$ZSAN received a discipline review letter (“DRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”).

$SRNE Sorrento Therapeutics S-3 Files To Sell $1.83M Shares Of Common Stock For Holders

BEÑO 
https://inbestia.com/analisis/finalizacion-mensual-y-trimestral-con-un-hipotetico-suelo

independientemente de indicadores tecnicos ... algunas velas mensuales al cierre ...

ACAD

TEVA

ARNA

AMRN

NVAX

BEAM
curioso el precio, soporte de canal ronda los 23,7

Moderna

esta para entrar, breakout de iHCH , esta calentito